CN107296805A - Antrodia camphorata compound and its extract are used for the purposes for preparing the medicine for the treatment of and prevention of neurodegenerative diseases - Google Patents
Antrodia camphorata compound and its extract are used for the purposes for preparing the medicine for the treatment of and prevention of neurodegenerative diseases Download PDFInfo
- Publication number
- CN107296805A CN107296805A CN201610229905.5A CN201610229905A CN107296805A CN 107296805 A CN107296805 A CN 107296805A CN 201610229905 A CN201610229905 A CN 201610229905A CN 107296805 A CN107296805 A CN 107296805A
- Authority
- CN
- China
- Prior art keywords
- compound
- antrodia camphorata
- anca
- antrocamol
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
Abstract
The invention discloses the purposes that a kind of Antrodia camphorata compound, extract are used to prepare the medicine for the treatment of and prevention of neurodegenerative diseases, the compound is represented with Formulas I：Wherein R1 is hydrogen or acetyl group, and R2 is
Description
Technical field
The present invention relates to a kind of compound of separated from Antrodia sesame, extract and application thereof, especially with regard to by the chemical combination
Thing and extract are applied to prepare the purposes of the medicine for the treatment of and prevention of neurodegenerative diseases.
Background technology
Antrodia camphorata (Antrodia camphorata), also known as antrodia, cinnamomum kanahirai hay mushroom or red antrodia etc., belong to Aphyllophorales
(Aphyllophorales), the perennial gill fungus mushroom of Polyporaceae (Polyporaceae), is Taiwan endemic species fungi, is only given birth to
On the hollow rotten heartwood inwall for being longer than Taiwan child care class seeds-cinnamomum kanehirai (Cinnamoum kanehirai Hay).Due to ox
Camphor tree distributed quantity is extremely rare, adds artificial fell trees unlawfully so that the wild Antrodia camphorata quantity that parasitism can grow wherein is more
Shape is rare, and because its sporophore growth is relatively slow, and growth period is also only in June between October, therefore price is held high very much
It is expensive.
In Antrodia camphorata numerous compositions with triterpene compound be studied it is most, triterpene compound is by 30 carbon members
Element is combined into the general name of hexagon or pentagon native compound, the bitter taste that Antrodia camphorata has i.e. essentially from triterpenes this into
Point.During nineteen ninety-five, Cherng et al. has found new with lumistane containing three kinds in Antrodia camphorata fructification extract
(ergostane) it is the triterpene compound of skeleton：Antcin A, antcin B and antcin C (Cherng, I.H., and
Chiang,H.C.1995.Three new triterpenoids from Antrodia
cinnamomea.J.Nat.Prod.58:365-371).Chen et al. has found zhankuic after extracting antrodia fructification with ethanol
Three kinds of triterpene compounds such as acid A, zhankuic acid B and zhankuic acid C (Chen, C.H., and Yang,
S.W.1995.New steroid acids from Antrodia cinnamomea ,-a fungus parasitic on
Cinnamomum micranthum.J.Nat.Prod.58:1655-1661).In addition, Chiang et al. in nineteen ninety-five also by son
It is respectively that sesquiterpene lactone (sesquiterpene lactone) spreads out with two kinds of bisphenols that other three kinds are found in entity extract
Biological new triterpene compound, this is antrocin, 4,7- dimethoxy -5- methyl isophthalic acids, 3- benzo dioxies ring (4,7-
Dimethoxy-5-methy-1,3-benzodioxole) and 2,2', 5,5'- tetramethoxy -3,4,3', 4'- it is double-(methylenedioxy)
Base -6,6'- dimethyl diphenyls (2,2', 5,5'-teramethoxy-3,4,3', 4'-bi-methylenedioxy-6,6'-
dimethylbiphenyl)(Chiang,H.C.,Wu,D.P.,Cherng,I.W.,and Ueng,C.H.1995.A
sesquiterpene lactone,phenyl and biphenyl compounds from Antrodia
cinnamomea.Phytochemistry.39:613-616).By 1996, Cherng et al. with same analysis method once again
It was found that four kinds of new triterpene compounds：antcin E、antcin F、methyl antcinate G、methyl
antcinate H(Cherng,I.H.,Wu,D.P.,and Chiang,H.C.1996.Triteroenoids from
Antrodia cinnamomea.Phytochemistry.41:263-267)；And Yang et al. is then found that two kinds with ergot steroid
Alkane is noval chemical compound zhankuic acid D, the zhankuic acid E of skeleton, and three kinds with lanostane (lanostane)
For the noval chemical compound of skeleton：15 α-acetyl-dehydrosulphurenic acid (15 α-acetyl-dehydrosulphurenic
Acid), dehydroeburicoic acid (dehydroeburicoic acid) is with removing water sulfurenic acid (dehydrasulphurenic
acid)(Yang,S.W.,Shen,Y.C.,and Chen,C.H.1996.Steroids and triterpenoids of
Antrodia cinnamomea-a fungus parasitic on Cinnamomum
micranthum.Phytochemistry.41:1389-1392)。
Alzheimer disease (Alzheimer's Disease, AD) is a kind of neurodegenerative disorders, brain can be caused to wither
Contract, the symptom such as loss of memory.Alzheimer disease account in dementia (dementia) six to seventy percent origin cause of formation, be one kind fall ill into
The continuation neurological dysfunction that journey is slow, constantly deteriorate over time.In 2010, the whole world had nearly 2,100 ten thousand to 3,500 ten thousand
Name patients with Alzheimer disease, and the related Lethal cases of Alzheimer disease are attributed to, about 48.6 ten thousand.Developing
In country, Alzheimer disease is one of suitable disease for expending social financial aid.
Brain kind of starch albumen β (amyloid- β, A β) accumulation is currently known, is the main cause for causing the disease.A β can be in
Deposition causes oxidative pressure and inflammatory response to make neuronal damage in brain, ultimately causes the obstacle of mnemonic learning ability.Therefore
Oxidation resistance has high correlation with prevention AD.PC-12 cells, which are commonly used for A β in simulation Alzheimer disease, to be injured
A kind of pattern of nerve cell, PC-12 nerve fibres mother cell can be differentiated under nerve growth factor (NGF) stimulation
The prominent structure of similar nerve, the physiological reaction behaved like is widely used in neurological research.
The content of the invention
It is an object of the invention to the A β using synthesis, with class nerve cell PC-12 co-incubations, Alzheimer is simulated
A β injure nerve cell in disease, come inquire into Antrodia camphorata extract (ANCA, ANCA-D) and compound (Antrocamol LT1,
LT2, LT3) influence to AD cell models.
Accordingly, the present invention provides the medicine that a kind of Antrodia camphorata compound is used to prepare treatment and prevention of neurodegenerative diseases
Purposes, shown in the Antrodia camphorata compound such as formula (I)：
Wherein R1 is hydrogen or acetyl group, and R2 is
It is preferred that the R1 of the wherein compound is hydrogen, R2 isRepresented with formula (II)：
It is preferred that the R1 of the wherein compound is acetyl group, R2 isRepresented with formula (III)：
It is preferred that the R1 of the wherein compound is hydrogen, R2 isRepresented with formula (IV)：
The present invention more provide a kind of Antrodia camphorata extract be used for prepare treat and prevention of neurodegenerative diseases medicine
Purposes, the wherein extract are so that the following steps are extracted and are obtained：Take Cinnamomum kanahirai hay camphorata mycelium, fructification or the mixture of the two with
Merging is concentrated to give one and slightly takes out thing after the alcohol of 10 times of amounts is extracted 2 times, and wherein the thick thing of taking out is the Antrodia camphorata extract.
It is preferred that wherein this slightly takes out thing further with methylene chloride/water (1:1) extraction is allocated 3 times, to be divided into
One dichloromethane layer and a water layer, the wherein dichloromethane layer are the Antrodia camphorata extract.
Brief description of the drawings
Figure 1A~1E show Antrodia camphorata extract (ANCA, ANCA-D) and compound (Antrocamol LT1, LT2,
LT3) to the influence of PC-12 cell growths；
Fig. 2A~2E show Antrodia camphorata extract (ANCA, ANCA-D) and compound (Antrocamol LT1, LT2,
LT3) therapeutic effect in vitro to AD cell models；
Fig. 3 A~3E show Antrodia camphorata extract (ANCA, ANCA-D) and compound (Antrocamol LT1, LT2,
LT3) preventive effect in vitro to AD cell models.
Embodiment
1. material and method
1.1 Experimental agents
Antrodia camphorata extract (ANCA, ANCA-D) and compound (Antrocamol LT1, LT2, LT3), it is biological by The Orchid Pavilion
Science and Technology Ltd. provides, -20 DEG C of preservations.
The extraction of Antrodia camphorata composition
Antrodia camphorata (Antrodia camphorata) mycelium, fructification or the mixture of the two (1.0kg) are taken with 10 times
After the alcohol of amount is extracted 2 times, merging concentration, which can be obtained, slightly takes out thing about 230g (ANCA), slightly takes out thing with methylene chloride/water (1:1) carry out
Distribute extraction 3 times, be divided into dichloromethane layer about 102.6g (ANCA-D) and water layer about 127.4g (ANCA-W), take dichloromethane
Layer 6.0g passes through n-hexane/dichloromethane (1 with silica gel column chromatography:4), dichloromethane, ethanol/methylene (5:95) molten
Matchmaker separates, and is divided into four layers of ANCA-E-D-1, ANCA-E-D-2, ANCA-E-D-3, ANCA-E-D-4 etc..Above-mentioned four layers of acquirement point
It is not：Merge n-hexane/dichloromethane (1:4) and dichloromethane be ANCA-E-D-1, ethanol/methylene (5:95) liquid is purged with
First half is ANCA-E-D-2, ethanol/methylene (5:95) liquid latter half is purged with for ANCA-E-D-3, finally with methanol
Purge with as ANCA-E-D-4.Associated materials and method see related journals document：Fitoterapia Volume 102,
April 2015,Pages 115–119。
Antrodia camphorata compound Antrocamol LT1, Antrocamol LT2, Antrocamol LT3
Antrodia camphorata compound Antrocamol LT1, Antrocamol LT2, Antrocamol LT3 are inventor
From in Antrodia camphorata extract it is purified obtained by three compounds, its purification process and Structural Identification are in previous application
Disclosed in, it is no longer repeated herein, only briefly explains its structural formula and its simple information, as follows：
Antrocamol LT1 are colourless product liquid, and the molecular formula through analyzing the compound is C24H38O5, molecular weight
For 406, complete Chinese illustrious name be referred to as 4- hydroxyl -2,3- dimethoxy -6- methyl -5- (9- hydroxyls -3,7,11- trimethyls -2,6,
The carbon triolefins of 10- 12) -2- cyclonenes, 4-hydroxy-5- [9-hydroxy-3,7,11-trimethyldodeca-2,6,
10-trienyl] -2,3-dimethoxy-6-me thyl-cyclohex-2-enone, its structural formula is as shown in Formula II：
Antrocamol LT2:For colourless product liquid, the molecular formula through analyzing the compound is C26H40O6；Molecular weight
For 448, complete Chinese illustrious name be referred to as 4- acetoxyl group -2,3- dimethoxy -6- methyl -5- (9- hydroxyls -3,7,11- trimethyls -
The carbon triolefins of 2,6,10- 12) -2- cyclonenes, 4-acetoxy-5- [9-hydroxy-3,7,11-trimethyldodeca-
2,6,10-trienyl]-2,3-dimethoxy-6-met hyl-cyclohex-2-enone.Its structural formula is as shown in formula III：
Antrocamol LT3:For colourless product liquid, the molecular formula through analyzing the compound is C24H38O5；Molecular weight
For 406；, complete China and British title is respectively (4R, 5R, 6R) -4- hydroxyls 5- [(2E, 6E, 9E) -11- hydroxyl -3,7,11- front threes
- 2,6,9- the trialkenyls of base-ten two] -2,3- dimethoxy -6- methyl-cyclohexyl -2- ketenes, (4R, 5R, 6R) -4-hydroxy-5-
[(2E,6E,9E)-11-hydroxy-3,7,11-trimethyldodeca-2,6,9-trien yl]-2,3-dimethoxy-
6-methylcyclohex-2-enone.Its structural formula is as shown in formula IV：
Above Antrocamol LT1, Antrocamol LT2 and Antrocamol LT3 have similar main structure, its
Formula can be represented shown in formula I：
Wherein, R1 is hydrogen or acetyl group, and R2 is
The details such as extraction and purifying on above-mentioned three kinds of Antrodia camphorata compounds, see the previous of inventor
Related application is (for example：Taiwan application for a patent for invention number is 103140521).Due to the compound such as this in previous application land
It is continuous to disclose with a variety of medical functions, at this to carrying out related experiment with above-mentioned extract and three kinds of compounds, detect it
For the influence of nerve degenerative diseases, examine whether that also there is doctor for the related neurodegenerative such as Alzheimer disease disease
Treat potentiality.
1.2 cell culture (Cell culture)
PC-12 nerve fibre mother cells, from the cell line of the pheochromocytoma of rat adrenal medulla.Cell line
(Cell line) purchased from Shanghai Inst. of Life Science, CAS cell resource center (200031, Shanghai,
China)。
1.3 main agents
RPMI 1640medium, WISENT；Fetal bovine serum (FBS), WISENT；Heat-
Inactivated Horse serum, Gibco；Penicillin-Streptomycin (100X), Beyotime；Dimethyl
Sulfoxide (DMSO), Sunshine Bio；Trypsin 1:250, Sunshine Bio；EDTA2Na, Sunshine Bio；
Phosphate buffered saline (PBS), Beyotime；NGF 2.5S Native Mouse Protein,
Invitrogen；Amyloid β Protein Fragment 1-40, Sigma-Aldrich；Trifluoroacetic acid
99%, TCI；CCK-8cell viability assay kit, Beyotime.
1.4 key instrument
FormaTMSeries 3 Water Jacketed CO2 Incubator, Thermo；MSC-AdvantageTM
Class II Biological Safety Cabinets, Thermo；ENTRIS64-1S Analytical Balance,
Sartorius；HH-4Digital Water bath, high honour instrument manufacturing Co., Ltd；SB25-12DT Ultrasonic
Cleaning, Xin Yi ultrasonic device Co., Ltd；MLS-3780Autoclave, SANYO；DHG-9423A Electric oven
Thermostat blast, three hair scientific instrument Co., Ltds；Bio-MEDICAL HYCD-282Ultra-Low
Temperature Freezers, Haier；Allegra X-15R Benchtop Centrifuge, Beckman；Eclipse
TS100Inverted Routine Microscope, Nikon；Infinite M1000PRO Microplate Readers,
TECAN。
2. experimental method
The culture of 2.1PC-12 nerve fibre parent cell lines
PC-12 nerve fibres mother cell is with RPMI 1640medium (serum of bovine containing 5%fetal, 10%
heat-inactivated horse serum、2mM glutamine、50U/mL penicillin、50mg/mL
Streptomycin), it is incubated at 37 DEG C, 5%CO2In the environment of, squamous subculture is twice weekly.
Before all experiments carried out in our current research, PC-12 cells need first containing mouse submandibular gland nerve growth factor
Preculture 72hr is to induce differentiation into neuron cell on the medium of sub (NGF 2.5S, 100ng/mL).
2.2 Antrodia camphorata extracts and compound the IC50 titration experiments in PC-12 cells
CCK-8assay allows to carry out Cell in cell propagation and cell toxicity test using sensitive colorimetric method
Viability measure.CCK-8 detection sensitivity is higher than other tetrazolium saltses, such as MTT, XTT, MTS or WST-1.Highly-water-soluble
Tetrazolium salts WST-8 is reduced by the dehydrogenase in cell, so as to obtain yellow product (formazans solvable in the medium), by thin
The amount that dehydrogenase activity in born of the same parents produces formazan dyestuffs is directly proportional to viable count.
In order to which the PC-12 neural models induced for NGF optimize Antrodia camphorata extract (ANCA, ANCA-D) and compound
The concentration of (Antrocamol LT1, LT2, LT3), has carried out titration experiments to determine its IC50 in PC-12 cells.By 5
× 104 are placed in 96-well with the NGF PC-12 cells treated and are cultivated 24hr, and medium is replaced by containing 1% afterwards
Fetal bovine serum, 2%heat-inactivated horse serum, 2mM glutamine, 50U/mL
Penicillin, 50mg/mL streptomycin RPMI 1640medium, and add with the various concentrations medicine of gradient dilution
Thing：ANCA, ANCA-D (0.064,0.32,1.6,8,40,200 μ g/mL), Antrocamol LT1, LT2, LT3 (0.032,
0.16,0.8,4,20,100 μ g/mL), each well DMSO concentration is no more than 0.5%, is incubated 24hr.Processing will after terminating
CCK-8solution is added in plate each well, is placed in Incubator and is incubated 4hr, in Microplate Readers
Detect the concentration of each well formazans product at OD 450nm, and Cell viability are expressed as relative to accordingly compareing
Percentage.
2.2 Antrodia camphorata extracts and compound induce PC-12 cell survivals to detect amyloid beta
Amyloid-beta 1-40 (A β 1-40) is dissolved in 0.1% (v/v) trifluoroacetic acid (TFA) water with 10mg/mL
In solution, -20 DEG C are stored in as stock solution.A β 1-40 stock solutions are diluted to 0.5mg/mL with PBS before experiment, and in
48hr is condensed at 25 DEG C.
In order to study ANCA, ANCA-D, Antrocamol LT1, LT2, LT3 are in vitro to Alzheimer disease
The therapeutic effect of (Alzheimer's Disease, AD) cell model, the PC-12 cells that 5 × 104 have been treated with NGF
It is placed in 96-well and cultivates 24hr, medium is replaced by the serum of bovine containing 1%fetal, 2%heat- afterwards
inactivated horse serum、2mM glutamine、50U/mL penicillin、50mg/mL streptomycin
RPMI 1640medium, and add 10 μM of A β 1-40 dilutions processing 24hr, be separately added into ANCA (5,10,20 μ g/mL),
ANCA-D (10,20,40 μ g/mL), Antrocamol LT1, LT2, LT3 (25,50,100 μ g/mL) are further cultured for 24hr.With without
Its OD value of cell of processing is crossed as control, Cell viability are calculated, both equal to medicine to A β 1-40 nerve cells poison
The inhibiting rate of property, is represented with %.Formula is as follows：
Cell viability (%)=(Sample-Blank)/(Control-Blank) × 100%
In order to study ANCA, ANCA-D, Antrocamol LT1, LT2, LT3 are to the preventive effects of AD cell models, by 5
× 104 are placed in 96-well with the NGF PC-12 cells treated and are cultivated 24hr, and medium is replaced by containing 1% afterwards
Fetal bovine serum, 2%heat-inactivated horse serum, 2mM glutamine, 50U/mL
Penicillin, 50mg/mL streptomycin RPMI 1640medium, and ANCA (5,10,20 μ are separately added into advance
G/mL), ANCA-D (10,20,40 μ g/mL), Antrocamol LT1, LT2, LT3 (25,50,100 μ g/mL) culture 24hr, then
10 μM of A β 1-40 dilutions processing 24hr are added, Cell viability measure is carried out afterwards.
3. experimental result
The influence of 3.1 Antrodia camphorata extracts and compound to PC-12 cell growths
By carrying out cell survival detection, it is respectively 22.91,49 to measure the IC50 of ANCA, ANCA-D in PC-12 cells
μ g/mL (Figure 1A~1B)；The IC50 of Antrocamol LT1, LT2, LT3 in PC-12 cells is respectively 178.5,168.5,
105.5 μ g/mL (Fig. 1 C~1E).
3.2 Antrodia camphorata extracts and compound induce amyloid beta the influence of PC-12 growths
ANCA, ANCA-D, Antrocamol LT1, Antrocamol LT2, Antrocamol LT3 are in vitro to A Er
The therapeutic effect of Ci Haimo disease (Alzheimer's Disease, AD) cell models, the result detected by cell survival shows
Show：ANCA, ANCA-D, Antrocamol LT1, Antrocamol LT2, Antrocamol LT3 can significantly suppress by A β
The damage of induction and improve its cell survival rate (Fig. 2A~2E).Wherein with ANCA, ANCA-D suppression damage relatively fruit preferably,
Secondly Antrocamol LT1, Antrocamol LT2 still significantly inhibit effect in 100 μ g/mL, 50 μ g/mL, to 25 μ g/
Effect is less obvious during mL, and Antrocamol LT3 still have inhibition when in 100 μ g/mL, 50 μ g/mL, and progressively
Drop to 25 μ g/mL effects unobvious.
ANCA, ANCA-D, Antrocamol LT1, Antrocamol LT2, Antrocamol LT3 are in vitro to A Er
The preventive effect of Ci Haimo disease (Alzheimer's Disease, AD) cell models, the result detected by cell survival shows
Show：ANCA, ANCA-D, Antrocamol LT1, Antrocamol LT2, Antrocamol LT3 are lured by A β preventing cell
Significant impact (Fig. 3 A~3E) is shown in terms of the neure damage (or reducing its risk) led.Wherein ANCA, ANCA-D
Preventive effect still highly significant, and Antrocamol LT1 even show ratio when concentration is 100,50,25 μ g/mL
ANCA, ANCA-D more preferably preventive effect, and Antrocamol LT2, Antrocamol LT3 effect are then poor.Each composition
It is shown go out difference on effect, may be relevant with involved mechanism difference, future can be for further being studied.However,
ANCA, ANCA-D, Antrocamol LT1, Antrocamol LT2, Antrocamol are at least had proven in this experiment
LT3 really in Alzheimer disease (Alzheimer's Disease, AD) cell model because caused by amyloid beta
The obvious effect of injury with suppression and prevention, therefore ANCA, ANCA-D extract and Antrocamol LT1, Antrocamol
LT2, Antrocamol LT3 compounds have in fact treat and prevention Alzheimer disease or other nerve degenerative diseases it is latent
Power.
As seen from the above embodiment, Antrodia camphorata compound provided by the present invention and its extract are used to prepare treatment nerve
The purposes of the medicine of degenerative disease really has a value in industry, and the narration of the above is only that presently preferred embodiments of the present invention is said
Bright, any those skilled in the art can make other a variety of improvement according to above-mentioned explanation, but these change
Become in the spiritual and bounded by right for still falling within the present invention.
Claims (6)
1. a kind of Antrodia camphorata compound is used for the purposes for preparing the medicine for the treatment of and prevention of neurodegenerative diseases, the Antrodia camphorata
Shown in compound such as formula (I)：
Wherein R1 is hydrogen or acetyl group, and R2 is
2. purposes according to claim 1, the wherein compound R 1 are hydrogen, R2Represented with formula (II)：
3. purposes according to claim 1, the wherein compound R 1 are acetyl group, R2With formula (III)
Represent：
4. the R1 of purposes according to claim 1, the wherein compound is hydrogen, R2With formula (IV)
Represent：
5. a kind of Antrodia camphorata extract is used for the purposes for preparing the medicine for the treatment of and prevention of neurodegenerative diseases, the wherein extraction
Thing is so that the following steps are extracted and are obtained：Cinnamomum kanahirai hay camphorata mycelium, fructification or the mixture of the two is taken to be taken out with the alcohol of 10 times of amounts
Take to merge after 2 times and be concentrated to give one and slightly take out thing, wherein the thick thing of taking out is the Antrodia camphorata extract.
6. purposes according to claim 5, wherein this slightly takes out thing further with methylene chloride/water (1:1) it is allocated
Extraction 3 times, to be divided into a dichloromethane layer and a water layer, the wherein dichloromethane layer is the Antrodia camphorata extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610229905.5A CN107296805A (en) | 2016-04-14 | 2016-04-14 | Antrodia camphorata compound and its extract are used for the purposes for preparing the medicine for the treatment of and prevention of neurodegenerative diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610229905.5A CN107296805A (en) | 2016-04-14 | 2016-04-14 | Antrodia camphorata compound and its extract are used for the purposes for preparing the medicine for the treatment of and prevention of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107296805A true CN107296805A (en) | 2017-10-27 |
Family
ID=60137079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610229905.5A Pending CN107296805A (en) | 2016-04-14 | 2016-04-14 | Antrodia camphorata compound and its extract are used for the purposes for preparing the medicine for the treatment of and prevention of neurodegenerative diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107296805A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111773254A (en) * | 2020-07-21 | 2020-10-16 | 浙江工业大学 | Application of antrodia camphorata triterpene in preparation of medicines for treating neurodegenerative diseases |
| CN113453689A (en) * | 2018-11-28 | 2021-09-28 | 吉亚生技控股股份有限公司 | Compositions and methods for treating dementia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104177240A (en) * | 2013-05-28 | 2014-12-03 | 曾卉菱 | Compound and extract isolated from Antrodia camphorata and application |
| CN104968339A (en) * | 2012-11-21 | 2015-10-07 | 国鼎生物科技股份有限公司 | Methods and compositions for treating neurodegenerative diseases |
-
2016
- 2016-04-14 CN CN201610229905.5A patent/CN107296805A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104968339A (en) * | 2012-11-21 | 2015-10-07 | 国鼎生物科技股份有限公司 | Methods and compositions for treating neurodegenerative diseases |
| CN104177240A (en) * | 2013-05-28 | 2014-12-03 | 曾卉菱 | Compound and extract isolated from Antrodia camphorata and application |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113453689A (en) * | 2018-11-28 | 2021-09-28 | 吉亚生技控股股份有限公司 | Compositions and methods for treating dementia |
| CN111773254A (en) * | 2020-07-21 | 2020-10-16 | 浙江工业大学 | Application of antrodia camphorata triterpene in preparation of medicines for treating neurodegenerative diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Farbood et al. | Ellagic acid prevents cognitive and hippocampal long-term potentiation deficits and brain inflammation in rat with traumatic brain injury | |
| Jessberger et al. | Dentate gyrus-specific knockdown of adult neurogenesis impairs spatial and object recognition memory in adult rats | |
| Sun et al. | Aconitine-induced Ca2+ overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats | |
| Heidari et al. | Memory enhancement and protective effects of crocin against D-galactose aging model in the hippocampus of Wistar rats | |
| Mishra et al. | Dopamine D1 receptor activation improves adult hippocampal neurogenesis and exerts anxiolytic and antidepressant-like effect via activation of Wnt/β-catenin pathways in rat model of Parkinson's disease | |
| Tang et al. | Cognitive enhancement and neuroprotective effects of OABL, a sesquiterpene lactone in 5xFAD Alzheimer's disease mice model | |
| Zhang et al. | Scorpion venom heat-resistant peptide protects transgenic Caenorhabditis elegans from β-amyloid toxicity | |
| Khotimah et al. | Decreasing α-synuclein aggregation by methanolic extract of Centella asiatica in zebrafish Parkinson's model | |
| Li et al. | Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-β peptides-induced oxidative stress in in-vivo and in-vitro models of Alzheimer's disease | |
| Wu et al. | Retracted: Effect of microRNA‐186 on oxidative stress injury of neuron by targeting interleukin 2 through the janus kinase‐signal transducer and activator of transcription pathway in a rat model of Alzheimer’s disease | |
| Zhang et al. | Perfluorooctane sulfonate induces apoptosis in N9 microglial cell line | |
| Zhang et al. | Curcumin derivative Cur20 attenuated cerebral ischemic injury by antioxidant effect and HIF-1α/VEGF/TFEB-activated angiogenesis | |
| CN107296805A (en) | Antrodia camphorata compound and its extract are used for the purposes for preparing the medicine for the treatment of and prevention of neurodegenerative diseases | |
| Uno et al. | Callyspongins A and B: novel polyacetylene sulfates from the marine sponge Callyspongia truncata that inhibit fertilization of starfish gametes | |
| Ma et al. | MG53 protects hUC-MSCs against inflammatory damage and synergistically enhances their efficacy in neuroinflammation injured brain through inhibiting NLRP3/caspase-1/IL-1β axis | |
| Yeh et al. | Pathobiological mechanisms of endothelial dysfunction induced by tert-butyl hydroperoxide via apoptosis, necrosis and senescence in a rat model | |
| Aquino et al. | Genotoxic evaluation of the antimalarial drugs artemisinin and artesunate in human HepG2 cells and effects on CASP3 and SOD1 gene expressions | |
| Apel et al. | N-myristoyltransferases inhibitory activity of ellagitannins from Terminalia bentzoë (L.) L. f. subsp. bentzoë | |
| Lee et al. | Potential analgesic and anti-inflammatory activities of Panax ginseng head butanolic fraction in animals | |
| Long et al. | Does exercise influence skeletal muscle by modulating mitochondrial functions via regulating MicroRNAs? A systematic review | |
| JP2017513807A (en) | Tansan extract and compounds | |
| Peng et al. | Pharmaceutical bioassays: methods and applications | |
| CN106905317B (en) | 4- replaces Sampangine alcaloid-derivatives and its synthetic method and application | |
| US20170273916A1 (en) | Methods for treating and preventing neurodegenerative diseases | |
| CN114668758A (en) | Application of artemisinin and derivatives thereof in preparation of ChAT activity enhancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171027 |